Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 6, 2000, Pages 2129-2134

  Rittmaster, Roger S ^a   Bolognese, Michael ^b   Ettinger, Mark P ^c   Hanley, David A ^d   Hodsman, Anthony B ^e   Kendler, David L ^f   Rosen, Clifford J ^g  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Bethesda Health Research   (United States)

^c Clin Res Center of South Florida   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN; CREATININE; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VERTEBRA;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FEMUR; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES; TERIPARATIDE; TIME FACTORS;

EID: 0034458020     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.6.2129     Document Type: Article

References (19)

1. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
2. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
3. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
4. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
5. Anabolic actions of parathyroid hormone on bone
6. Anabolic effects of parathyroid hormone on bone
7. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis
8. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone vs. cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
9. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
10. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers
11. A clinical trial of cyclical clodronate as maintenance therapy following withdrawal of parathyroid hormone, in the treatment of post-menopausal osteoporosis
12. A randomized controlled multi-centre study of 1-84hPTH for treatment of posmenopausal osteoporosis
13. Maintenance of bone gained after PTH treatment of ovariectomized, osteopenic rats by bisphosphonate or reduced PTH
14. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial
15. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial
16. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride
17. Parathyroid hormone (PTH1-34) increases cancellous bone mass markedly in men with idiopathic osteoporosis
18. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
19. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats